SDCBP and colorectal carcinoma: In cell lines of colorectal carcinoma (SW480, SW620, and Caco2) treated with shRNA against syntenin-1, Iwamoto et al. observed a diminution in the migration capacity and chemoresistance to L-OHP (Oxaliplatin) in the three cell lines.